3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Classical hematology
1
Conditions
Breast Neoplasms
14
Polycystic Ovary Syndrome
9
Neoplasms
5
Endometrial Neoplasms
3
Prostatic Neoplasms
2
Peripheral Nervous System Diseases
2
Obesity
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Melanoma
2
Leukemia, Myeloid, Acute
2
Leiomyoma
2
Insulin Resistance
2
Inflammation
2
Infertility, Female
2
Glioblastoma
2
Diabetes Mellitus
2
Colorectal Neoplasms
2
Cognitive Dysfunction
2
Cardiotoxicity
2
Weight Gain
1
Vomiting
1
Venous Thromboembolism
1
Vascular Malformations
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Triple Negative Breast Neoplasms
1
Thrombocythemia, Essential
1
Stem Cell Transplant Complications
1
Interventions
Cyclophosphamide
81
fludarabine phosphate
77
Peripheral Blood Stem Cell Transplantation
62
Mycophenolic Acid
55
Tacrolimus
54
Whole-Body Irradiation
52
Busulfan
51
Antilymphocyte Serum
45
Cyclosporine
41
fludarabine
36
Methotrexate
32
Filgrastim
32
Melphalan
30
Radiotherapy
25
Methylprednisolone
19
Cytarabine
17
Cord Blood Stem Cell Transplantation
17
Sirolimus
15
Azacitidine
15
Granulocyte Colony-Stimulating Factor
14
Alemtuzumab
14
thymoglobulin
13
Flow Cytometry
13
Etoposide
13
Cyclosporins
13
Specimen Handling
10
Biopsy
10
Thiotepa
9
Psychiatric Rehabilitation
9
Decitabine
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Myeloproliferative Disorders
×
Tablets
×
Clear all
NCT04243122
2024-05-29
AIRPORT-MPN
Ottawa Hospital Research Institute
Phase 2
Completed
44 enrolled